Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine Griffett

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
ACS Pharmacology & Translational Science|June 17, 2022
Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential AlternativeKristine Griffett
Bioorganic & Medicinal Chemistry Letters|March 14, 2013
The mammalian clock and chronopharmacologyKristine Griffett, Thomas P Burris
Biochemical and Biophysical Research Communications|September 30, 2016
Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver diseaseKristine Griffett, Thomas P Burris
Frontiers in Medicine|February 23, 2023
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseasesKristine Griffett, Thomas P Burris
Plos One|October 1, 2020
REV-ERB agonism improves liver pathology in a mouse model of NASHKristine Griffett, Gonzalo Bedia-Diaz, Bahaa Elgendy, et al.
ACS Pharmacology & Translational Science|November 8, 2019
Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver DiseaseMonideepa Sengupta, Kristine Griffett, Colin A Flaveny, et al.
Acta Pharmacologica Sinica|February 26, 2022
The role of REV-ERB in NASHKristine Griffett, Matthew E Hayes, Michael P Boeckman, et al.
Frontiers in Pharmacology|May 8, 2023
REV-ERB activation as a novel pharmacological approach for treating inflammatory painSangeet Makhija, Joshua D Griffett, Giri Babu Veerakanellore, et al.
Journal of Lipid Research|September 7, 2025
Cyclopropane xenolipids resemble monounsaturated fatty acids and modulate peroxisome proliferator-activated receptorsJean Debédat, Lorena Pastor, Trina A Knotts, et al.
ACS Chemical Biology|December 15, 2012
A liver-selective LXR inverse agonist that suppresses hepatic steatosisKristine Griffett, Laura A Solt, Bahaa El-Dien M El-Gendy, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
ACS Pharmacology & Translational Science|June 17, 2022
Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential AlternativeKristine Griffett
Bioorganic & Medicinal Chemistry Letters|March 14, 2013
The mammalian clock and chronopharmacologyKristine Griffett, Thomas P Burris
Biochemical and Biophysical Research Communications|September 30, 2016
Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver diseaseKristine Griffett, Thomas P Burris
Frontiers in Medicine|February 23, 2023
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseasesKristine Griffett, Thomas P Burris
Plos One|October 1, 2020
REV-ERB agonism improves liver pathology in a mouse model of NASHKristine Griffett, Gonzalo Bedia-Diaz, Bahaa Elgendy, et al.
ACS Pharmacology & Translational Science|November 8, 2019
Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver DiseaseMonideepa Sengupta, Kristine Griffett, Colin A Flaveny, et al.
Acta Pharmacologica Sinica|February 26, 2022
The role of REV-ERB in NASHKristine Griffett, Matthew E Hayes, Michael P Boeckman, et al.
Frontiers in Pharmacology|May 8, 2023
REV-ERB activation as a novel pharmacological approach for treating inflammatory painSangeet Makhija, Joshua D Griffett, Giri Babu Veerakanellore, et al.
Journal of Lipid Research|September 7, 2025
Cyclopropane xenolipids resemble monounsaturated fatty acids and modulate peroxisome proliferator-activated receptorsJean Debédat, Lorena Pastor, Trina A Knotts, et al.
ACS Chemical Biology|December 15, 2012
A liver-selective LXR inverse agonist that suppresses hepatic steatosisKristine Griffett, Laura A Solt, Bahaa El-Dien M El-Gendy, et al.
Pageof 3